Who
Steven Chan
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Attovia Therapeutics; Officer, Arcus Biosciences; Officer, MyoKardia.
In numbers
- Trades disclosed
- 5
- Buys
- 0
- Sells
- 0
- Bought
- $0
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 2 Feb 2016
- Last trade
- 4 Aug 2026
- Last filed
- 8 Oct 2026
Companies traded
Activity over time
Not enough dated trades to draw.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Aug 2026filed 8 Oct 2026 | ATTO Attovia Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —140,000 at $0.00 | filing |
| 16 Jan 2019filed 18 Jan 2019 | RCUS Arcus Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —35,000 at $0.00 | filing |
| 18 Jan 2017filed 20 Jan 2017 | MyoKardiaoption or derivative | SEC FORM 4 Code A | —25,000 at $0.00 | filing |
| 1 Nov 2016filed 2 Nov 2016 | MyoKardiaoption or derivative | SEC FORM 4 Code A | —2,041 at $0.00 | filing |
| 2 Feb 2016filed 4 Feb 2016 | MyoKardiaoption or derivative | SEC FORM 4 Code A | —23,800 | filing |
News
No headline names them, or the companies they trade most, lately.
Sectors
No trade we could place in a sector.